Southfield, MINCT07363720Now EnrollingIRB Ready

Narcolepsy Type 1 (NT1) Clinical Trial in Southfield, MI

Access cutting-edge narcolepsy type 1 (nt1) treatment through this clinical trial at a research site in Southfield. Study-provided care at no cost to qualified participants.

Sponsored by Takeda

Quick Self-Assessment

See if you qualify for this Southfield location

Preparing your pre-screening questions…

Expert Care in Southfield

Access narcolepsy type 1 (nt1) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related narcolepsy type 1 (nt1) treatment provided free

Apply for This Southfield Location

Check if you qualify for this narcolepsy type 1 (nt1) clinical trial in Southfield, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Southfield

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Southfield site if eligible
  4. 4Begin participation

About This Narcolepsy Type 1 (NT1) Study in Southfield

The main aim of this study is to assess how effective TAK-861 is for treating narcolepsy type 1 and if this effect is maintained over time. Participants will take TAK-861 for a few months and if they meet certain criteria, they will be randomly assigned (by chance, like flipping a coin) to continue taking TAK-861 or take placebo (fake medicine) for up to 4 weeks to see if their narcolepsy symptoms return.

Sponsor: Takeda

Who Can Participate

Inclusion Criteria

The participant has a body mass index (BMI) within the range 18 to 40 kilograms per square meter (kg/m\^2).
The participant has an International Classification of Sleep Disorders, Third Edition (ICSD-3) or International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) diagnosis of NT1.
The participant is positive for the human leukocyte antigen (HLA) genotype Major Histocompatibility Complex, Class II, DQ Beta 1 (HLA-DQB1\*06:02) or results from radioimmunoassay indicate the participant's CSF OX/hypocretin-1 concentration is ≤110 pg/mL (or less than one-third of the mean values obtained in normal participants within the same standardized assay).

Exclusion Criteria

The participant has a current medical disorder, other than narcolepsy with cataplexy, associated with EDS.
The participant a) has a history of myocardial infarction, b) has a history of clinically significant hepatic disease, thyroid disease, coronary artery disease, cardiac rhythm abnormality or heart failure, or c) has any medical condition (such as unstable cardiovascular, pulmonary, renal or gastrointestinal disease.
The participant has current or recent (within 6 months) gastrointestinal disease that is expected to influence the absorption of drugs.
The participant has a history of cancer in the past 5 years.
The participant has a clinically significant history of head injury or head trauma.
The participant has a history of epilepsy, seizure, or convulsion (except for a single febrile seizure in childhood).
The participant has a history of cerebral ischemia, transient ischemic attack (less than 5 years from screening), intracranial aneurysm, or arteriovenous malformation.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Southfield?

Yes, this clinical trial (NCT07363720) has an active research site in Southfield, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Narcolepsy Type 1 (NT1) Treatment Options in Southfield, MI

If you're searching for narcolepsy type 1 (nt1) treatment options in Southfield, MI, this clinical trial (NCT07363720) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Southfield research site is actively enrolling participants for this clinical trial. You'll receive care from experienced narcolepsy type 1 (nt1) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all narcolepsy type 1 (nt1) clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Southfield, MI

See all pulmonary embolism clinical trials recruiting in Southfield — not just this study.

Browse Pulmonary Embolism Trials in Southfield →

Browse More Trials by Condition

Pulmonary Embolism TrialsNarcolepsy TrialsNarcolepsy Type 1 TrialsAll Conditions →

Ready to Join in Southfield?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Southfield, MI